Navigation Links
Pfenex Inc. and Agila Biotech Private Limited Announce Joint Venture to Develop Biosimilar Products for the Global Market

SAN DIEGO and BANGALORE, India, April 16, 2013 /PRNewswire/ -- Pfenex Inc. and Agila Biotech Private Limited, a subsidiary of Strides Arcolab Limited today announced that they have entered into a joint venture to develop, manufacture and commercialize an initial pipeline of six biosimilar products for the global market. Operating as a JV, wherein both parties will equally share in decision making regarding product development and commercialization, Agila Biotech will be a 51% equity stakeholder.  This multi-product joint venture combines Pfenex's industry-leading expertise in strain engineering and process development with Agila Biotech's biologics manufacturing and clinical development excellence. The lead product for the joint venture is Interferon beta-1b, a biosimilar to Betaseron®, indicated for relapsing-remitting and secondary-progressive forms of multiple sclerosis, commencing human clinical trials by Q4 2013.  Under the terms of the agreement, Pfenex will assume primary responsibility for development of  an optimized production strain, process and analytical package for each product, while Agila Biotech will be responsible for pre-clinical and Phase 1 development, as well as cGMP manufacturing.  The joint venture will then progress the products through Phase 3 and into commercialization.  Manufacture of the collaboration products will be carried out at Agila Biotech's state-of-the-art manufacturing facility being built with Bio-XCell at Nusajaya, Johor, Malaysia – a 160 acre site comprised of customized biotech facilities.

"One of the global challenges for the future of healthcare is to develop and produce products within the confines of a constrained cost environment," said Dr. Bertrand Liang , CEO at Pfenex. "Biosimilars are and will play an increasingly important role in patient disease management. This venture between Pfenex and Agila Biotech will allow us to leverage our infrastructure for the development of safe, reliable and cost-effective therapies for patients to address unmet medical needs all over the world."

"Successful foray into the biologics space for companies like Agila Biotech would hinge not only on building a state-of-the-art infrastructure and strong technical foundation, but also on creative partnerships such as the one that Agila Biotech has entered into with Pfenex.  This will allow us to not only leverage time and cost advantage of developing products in India and Malaysia, but also serve as a gateway to a vast region in South Asia, South-East Asia and the OIC region currently underserved as a result of the lack of high quality, cost effective biologics," said Dr. Anand Iyer , CEO at Agila Biotech.  Dr. Iyer also noted that its facility in Malaysia represents a strategic move to bolster Agila Biotech's manufacturing presence in the region and tap into unmet global demand for quality biologics at affordable prices.

About Agila Biotech Private Limited (India) / Strides Arcolab Limited: 

Agila Biotech Private Limited, India is a wholly owned subsidiary of Strides Acrolab Limited (Strides). Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of pharmaceutical products.  The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at Strides' website at

About Pfenex Inc.: Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  Utilizing the company's core technology, Pfenex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality therapeutics. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division.  For more information please visit

SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
2. Epsen Fuller Group Recruits Operations Leader for Global Biotech Firm SOTIO
3. Equatorial Guineas [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech (OTCBB:TNIB) to launch major innovative health solutions and improve pharmaceutical quality for its citizens
4. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
5. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
7. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
8. Regulus to Present at Future Leaders in the Biotech Industry Conference
9. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
10. Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
11. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
Post Your Comments:
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):